Kezar Life Sciences, Inc. (KZR)
7.29
0.00 (0.00%)
USD |
NASDAQ |
Sep 02, 16:00
Kezar Life Sciences Cash from Investing (Quarterly) : 1.529M for March 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 1.529M |
| December 31, 2025 | 51.61M |
| September 30, 2025 | 15.71M |
| June 30, 2025 | 11.40M |
| March 31, 2025 | 13.74M |
| December 31, 2024 | 23.74M |
| September 30, 2024 | 24.06M |
| June 30, 2024 | 12.22M |
| March 31, 2024 | 20.41M |
| December 31, 2023 | 27.88M |
| September 30, 2023 | 18.57M |
| June 30, 2023 | 13.20M |
| March 31, 2023 | 16.39M |
| December 31, 2022 | -8.661M |
| September 30, 2022 | -24.71M |
| June 30, 2022 | 1.51M |
| March 31, 2022 | -59.53M |
| December 31, 2021 | -82.49M |
| September 30, 2021 | 38.48M |
| Date | Value |
|---|---|
| June 30, 2021 | 16.25M |
| March 31, 2021 | -0.687M |
| December 31, 2020 | 17.32M |
| September 30, 2020 | 2.79M |
| June 30, 2020 | -37.28M |
| March 31, 2020 | -39.33M |
| December 31, 2019 | 1.678M |
| September 30, 2019 | 15.62M |
| June 30, 2019 | 2.142M |
| March 31, 2019 | 0.976M |
| December 31, 2018 | -9.916M |
| September 30, 2018 | -56.67M |
| June 30, 2018 | -17.12M |
| March 31, 2018 | -0.195M |
| December 31, 2017 | -0.063M |
| September 30, 2017 | -0.326M |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| NovelStem International Corp. | 0.00 |
| Brainstorm Cell Therapeutics, Inc. | 0.00 |
| Summit Therapeutics, Inc. | 222.41M |
| Protara Therapeutics, Inc. | 17.75M |
| Clene, Inc. | -0.001M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -7.445M |
| Cash from Financing (Quarterly) | 0.267M |
| Free Cash Flow | -42.03M |
| Free Cash Flow Per Share (Quarterly) | -1.014 |
| Free Cash Flow to Equity (Quarterly) | -6.473M |
| Free Cash Flow to Firm (Quarterly) | -7.445M |
| Free Cash Flow Yield | -78.70% |